Previous 10 | Next 10 |
home / stock / acogf / acogf news
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing, the Company is...
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a second closing pursuant to its previously announced private placement of units of the Company. Pursuant to the second closing, the Company ...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“...
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before deducting the placement agent’s fees and ot...
2023-08-22 17:01:58 ET More on Alpha Cognition FDA accepts Alpha Cognition's ALPHA-1062 IND for review Seeking Alpha’s Quant Rating on Alpha Cognition Earnings data for Alpha Cognition For further details see: Alpha Cognition GAAP EPS of -$0.03
Not for distribution in the U.S. or to U.S. newswire services. Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the l...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office ...
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22 nd are now available for online viewing. REGISTER NOW AT : https://...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGIST...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant f...
News, Short Squeeze, Breakout and More Instantly...
The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Pro...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...